Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

被引：37

作者：

Graham, Donna M. ^{[1
]}

Coyle, Vicky M. ^{[1
]}

Kennedy, Richard D. ^{[1
]}

Wilson, Richard H. ^{[1
]}

机构：

[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland

来源：

CURRENT COLORECTAL CANCER REPORTS | 2016年 / 12卷 / 03期

关键词：

Colorectal cancer; Biomarker stratification; Targeted therapy; Pathways; Molecular subtypes; Personalized medicine trials; Microsatellite instability; RAS; BRAF; EGFR; c-MET; HER2;

D O I：

10.1007/s11888-016-0312-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.

引用

页码：141 / 150

页数：10

共 83 条

[61] Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer [J].

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Bang, Yung-Jue ;

Camidge, D. Ross ;

Solomon, Benjamin J. ;

Salgia, Ravi ;

Riely, Gregory J. ;

Varella-Garcia, Marileila ;

Shapiro, Geoffrey I. ;

Costa, Daniel B. ;

Doebele, Robert C. ;

Long Phi Le ;

Zheng, Zongli ;

Tan, Weiwei ;

Stephenson, Patricia ;

Shreeve, S. Martin ;

Tye, Lesley M. ;

Christensen, James G. ;

Wilner, Keith D. ;

Clark, Jeffrey W. ;

Iafrate, A. John .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21) :1963-1971

[62] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[63]

Siena S, 2015, J CLIN ONCOL S, V33

[64] Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer [J].

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Balfour, Julia ;

Bardelli, Alberto .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (19) :1308-1324

[65] Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy [J].

Sinicrope, Frank A. ;

Mahoney, Michelle R. ;

Smyrk, Thomas C. ;

Thibodeau, Stephen N. ;

Warren, Robert S. ;

Bertagnolli, Monica M. ;

Nelson, Garth D. ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Alberts, Steven R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3664-+

[66] Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J].

Soda, Manabu ;

Choi, Young Lim ;

Enomoto, Munehiro ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Ishikawa, Shunpei ;

Fujiwara, Shin-ichiro ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Bando, Masashi ;

Ohno, Shoji ;

Ishikawa, Yuichi ;

Aburatani, Hiroyuki ;

Niki, Toshiro ;

Sohara, Yasunori ;

Sugiyama, Yukihiko ;

Mano, Hiroyuki .

NATURE, 2007, 448 (7153) :561-U3

[67]

Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMx150034, 10.1056/NEJMoa1408440]

[68] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].

Sorlie, T ;

Perou, CM ;

Tibshirani, R ;

Aas, T ;

Geisler, S ;

Johnsen, H ;

Hastie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Thorsen, T ;

Quist, H ;

Matese, JC ;

Brown, PO ;

Botstein, D ;

Lonning, PE ;

Borresen-Dale, AL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874

[69] Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas [J].

Spier, Isabel ;

Holzapfel, Stefanie ;

Altmueller, Janine ;

Zhao, Bixiao ;

Horpaopan, Sukanya ;

Vogt, Stefanie ;

Chen, Sophia ;

Morak, Monika ;

Raeder, Susanne ;

Kayser, Katrin ;

Stienen, Dietlinde ;

Adam, Ronja ;

Nuernberg, Peter ;

Plotz, Guido ;

Holinski-Feder, Elke ;

Lifton, Richard P. ;

Thiele, Holger ;

Hoffmann, Per ;

Steinke, Verena ;

Aretz, Stefan .

INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) :320-331

[70] Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan [J].

Spindler, Karen-Lise Garm ;

Pallisgaard, Niels ;

Vogelius, Ivan ;

Jakobsen, Anders .

CLINICAL CANCER RESEARCH, 2012, 18 (04) :1177-1185

← 1 2 3 4 5 6 7 8 9 →